Antiphospholipid syndrome: Laboratory detection, mechanisms of action and treatment

Journal of Internal Medicine

Volumn 270, Issue 2, 2011, Pages 110-122

  Tripodi, A ^a   de Groot, P G ^b   Pengo, V ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Arterial thromboembolism; Foetal loss; Laboratory testing; Pregnancy complications; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; GLYCOPROTEIN 1 BETA2 ANTIBODY; GLYCOPROTEIN IB; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CORTICOSTEROID THERAPY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS WASTAGE; HUMAN; IMMUNOPATHOGENESIS; LABORATORY DIAGNOSIS; LOW DRUG DOSE; NONHUMAN; PLASMAPHERESIS; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; SCREENING; THROMBOSIS PREVENTION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 79959382588     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02362.x     Document Type: Review

References (112)

1. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Harris EN, Gharavi AE, Boey ML et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-4.
3. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-45.
4. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986; 146: 2153-6.
5. Harris EN. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990; 94: 476-84.
6. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies. Am J Clin Pathol 1994; 101: 616-24.
7. Pierangeli SS, Stewart M, Silva LK, Harris EN. An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol 1998; 25: 156-60.
8. Coulam CB, McIntyre JA, Wagenknecht D, Rote N. Interlaboratory inconsistencies in detection of anticardiolipin antibodies. Lancet 1990; 335: 865.
9. Peaceman AM, Silver RK, MacGregor SN, Socol ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 1992; 166(6 Pt 1): 1780-4. discussion 1784-7.
10. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002; 118: 548-57.
11. Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A, Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb Res 2007; 120: 127-33.
12. Favaloro EJ, Wong RC, Jovanovich S, Roberts-Thomson P. A Review of beta2-glycoprotein-l antibody testing results from a peer-driven multilaboratory quality assurance program. Am J Clin Pathol 2007; 127: 441-8.
13. Cavazzana A, Pengo V, Tonello M et al. Anti-beta(2)-glycoprotein I ELISA assay: the influence of different antigen preparations. Thromb Haemost 2009; 101: 789-91.
14. Tripodi A. Laboratory testing for lupus anticoagulants: diagnostic criteria and use of screening, mixing, and confirmatory studies. Semin Thromb Hemost 2008; 34: 373-9.
15. Pengo V, Biasiolo A, Gresele P et al., Participating Centres of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007; 5: 925-30.
16. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
17. Pengo V, Tripodi A, Reber G et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7: 1737-40.
18. Jacobsen EM, Wisløff F. False negative screening tests for lupus anticoagulants - an unrecognized problem? Thromb Res 1996; 82: 445-51.
19. Devreese KM. No more mixing tests required for integrated assay systems in the laboratory diagnosis of lupus anticoagulants? J Thromb Haemost 2010; 8: 1120-2.
20. Tripodi A, Mancuso ME, Chantarangkul V et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII. Considerations on the differentiation between the two circulating anticoagulants. Clin Chem 2005; 51: 1883-5.
21. Jankowski M, Vreys I, Wittevrongel C et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 157-62.
22. Pierangeli SS, Chen PP, Raschi E et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236-50.
23. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardioplipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.
24. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
25. de Laat HB, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. Beta 2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598-602.
26. Haupt H, Schwick HG, Störiko K. On a hereditary beta-2-glycoprotein I deficiency. Humangenetik 1968; 5: 291-3.
27. 2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-74.
28. Agar C, van Os GM, Mörgelin M et al. {beta}2-Glycoprotein I can exist in two conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 1336-43.
29. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-32.
30. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng T, Bouma BN, de Groot PG. Antiphospholipid antibodies are directed to a combination of phospholipids with prothrombin, protein C or protein S. An explanation for their pathogenic mechanism? Blood 1993; 81: 2618-25.
31. Oosting JD, Preissner KT, Derksen RHWM, de Groot PG. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro. Br J Haematol 1993; 85: 761-8.
32. Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91: 1999-2004.
33. Hurtado V, Montes R, Gris JC et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood 2004; 104: 1369-74.
34. Rao LV, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996; 88: 4173-82.
35. Dombroski D, Balasubramanian K, Schroit AJ. Phosphatidylserine expression on cell surfaces promotes antibody-dependent aggregation and thrombosis in beta2-glyoprotein I-immune mice. J Autoimmun 2000; 14: 221-9.
36. Salemink I, Blezer R, Willems GM, Galli M, Bevers E, Lindhout T. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000; 84: 653-6.
37. Steffano B, Forastiero R, Martinuzzo M, Kordich L. Low plasma protein Z levels in patients with antiphospholipid antibodies. Blood Coagul Fibrinolysis 2001; 12: 411-2.
38. Rahgozar S, Yang Q, Giannakopoulos B, Yan X, Miyakis S, Krilis SA. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation. Arthritis Rheum 2007; 56: 605-13.
39. Jones DW, MacKie IJ, Gallimore MJ, Winter M. Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol 2001; 113: 550-2.
40. Rahgozar S, Giannakopoulos B, Yan X et al. Beta2-glycoprotein I protects thrombin from inhibition by heparin cofactor II: potentiation of this effect in the presence of anti-beta2-glycoprotein I autoantibodies. Arthritis Rheum 2008; 58: 1146-55.
41. Donohoe S, Quenby S, Mackie I et al. Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal and heparin-treated antiphospholipid syndrome pregnancies. Lupus 2002; 11: 11-20.
42. Pengo V, Brocco T, Biasiolo A, Rampazzo P, Carraro P, Zamarchi R. Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity. Blood 1999; 94: 3814-9.
43. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007; 109: 1490-4.
44. Willems GM, Janssen MP, Pelsers MM et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-42.
45. Rand JH, Wu XX, Andree HA et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997; 337: 154-60.
46. Bevers EM, Janssen MP, Willems GM, Zwaal RF. No evidence for enhanced thrombin formation through displacement of annexin V by antiphospholipid antibodies. Thromb Haemost 2000; 83: 792-4.
47. Willems GM, Janssen MP, Comfurius P, Galli M, Zwaal RF, Bevers EM. Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes. Biochemistry 2000; 39: 1982-9.
48. Brachvogel B, Dikschas J, Moch H et al. Annexin A5 is not essential for skeletal development. Mol Cell Biol 2003; 23: 2907-13.
49. Cugno M, Cabibbe M, Galli M et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103: 2121-6.
50. Cesarman-Maus G, Ríos-Luna NP, Deora AB et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006; 107: 4375-82.
51. Nakagawa H, Yasuda S, Matsuura E et al. Nicked {beta}2-glycoprotein I binds angiostatin 4.5 (plasminogen kringle 1-5) and attenuates its antiangiogenic property. Blood 2009; 114: 2553-9.
52. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood 2010; 116: 529-36.
53. Holers VM, Girardi G, Mo L et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-20.
54. Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-54.
55. Stewart MW, Etches WS, Gordon PA. Antiphospholipid antibody-dependent C5b-9 formation. Br J Haematol 1997; 96: 451-7.
56. Redecha P, Tilley R, Tencati M et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110: 2423-31.
57. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-87.
58. 2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost 2006; 4: 1680-90.
59. Shi T, Giannakopoulos B, Yan X et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54: 2558-67.
60. Sikara MP, Routsias JG, Samiotaki M, Panayotou G, Moutsopoulos HM, Vlachoyiannopoulos PG. {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood 2010; 115: 713-23.
61. Forastiero R, Martinuzzo M, Carreras LO, Maclouf J. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. J Thromb Haemost 1998; 79: 42-5.
62. Raschi E, Testoni C, Bosisio D et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-500.
63. Satta N, Dunoyer-Geindre S, Reber G et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007; 109: 1507-14.
64. Carreras LO. Vermylen 'Lupus' anticoagulant and prostacyclin. Lancet 1981; 1: 665.
65. Sorice M, Longo A, Capozzi A et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56: 2687-97.
66. Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, Kveder T. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res 2006; 118: 455-61.
67. Redecha P, Franzke CW, Ruf W, Mackman N, Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008; 118: 3453-61.
68. Di Simone N, Marana R, Castellani R et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum 2010; 62: 1504-12.
69. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57: 1487-95.
70. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
71. Finazzi G, Marchioli R, Brancaccio V et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
72. Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-42.
73. Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004; 164: 668-73.
74. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-8.
75. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454-545.
76. Prandoni P, Prins MH, Lensing AW et al., AESOPUS Investigators. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009; 150: 577-85.
77. Palareti G, Cosmi B, Legnani C et al., PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-9.
78. Cosmi B, Legnani C, Tosetto A et al., PROLONG Investigators (on behalf of Italian Federation of Anticoagulation Clinics). Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 2010; 115: 481-8.
79. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
80. Robert A, Le Querrec A, Delahousse B et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome - influence of the lupus anticoagulant on International Normalized Ratio. Groupe Méthodologie en Hémostase du Groupe d'Etudes sur l'Hémostases et la Thrombose. Thromb Haemost 1998; 80: 99-103.
81. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-15.
82. Levine SR, Brey RL, Tilley BC et al., APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.
83. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 630S-69S.
84. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-74.
85. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2study): a randomised controlled trial. Lancet 2002; 360: 109-13.
86. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9.
87. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-7.
88. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-13.
89. Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009; 123: 482-7.
90. Ruffatti A, Olivieri S, Tonello M et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008; 6: 1693-6.
91. Tincani A, Branch W, Levy RA et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12: 524-9.
92. Ruiz-Irastorza G, Khamashta MA. Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy. Ann N Y Acad Sci 2005; 1051: 606-12.
93. Ruffatti A, Tonello M, Del Ross T et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96: 337-41.
94. Ruffatti A, Calligaro A, Hoxha A et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 2010; 62: 302-7.
95. Ruffatti A, Marson P, Pengo V et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 2007; 6: 196-202.
96. Asherson RA, Espinosa G, Cervera R, Font J, Reverter JC. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol 2002; 8: 157-65.
97. Asherson RA, Cervera R, de Groot PG et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-4.
98. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 2003; 48: 3320-7.
99. Marson P, Bagatella P, Bortolati M et al. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. J Intern Med 2008; 264: 201-3.
100. Bortolati M, Marson P, Fabris F et al. Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature. Autoimmun Rev 2009; 8: 297-301.
101. Kumar D, Roubey RA. Use of rituximab in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12: 40-4.
102. Galli M, Borrelli G, Jacobsen EM et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110: 1178-83.
103. de Laat B, Pengo V, Pabinger I et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-73.
104. de Laat B, Derksen RH, Reber G et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost 2011; 9: 149-153.
105. Detkov PY, Gil-Aguado A, Lavilla P, Cuesta MV, Fontán G, Pascual-Salcedo D. Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome? Lupus 1999; 8: 430-8.
106. Lee EY, Lee CK, Lee TH et al. Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res 2003; 111: 29-32.
107. Sailer T, Zoghlami C, Kurz C et al. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost 2006; 95: 796-801.
108. Zoghlami-Rintelen C, Vormittag R, Sailer T et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 2005; 3: 1160-5.
109. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 147-52.
110. Hulstein JJ, Lenting PJ, de Laat B, Derksen RH, Fijnheer R, de Groot PG. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110: 1483-91.
111. Yu P, Passam FH, Yu DM, Denyer G, Krilis SA. Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. J Thromb Haemost 2008; 6: 1215-23.
112. Matsuura E, Kobayashi K, Matsunami Y, Lopez LR. The immunology of atherothrombosis in the antiphospholipid syndrome: antigen presentation and lipid intracellular accumulation. Autoimmun Rev 2009; 8: 500-5.